Galectin Therapeutics (GALT) Tops Q1 EPS by 5c

Galectin Therapeutics (NASDAQ: GALT) reported Q1 EPS of ($0.15), $0.05 better than the analyst estimate of ($0.20).

For earnings history and earnings-related data on Galectin Therapeutics (GALT) click here.

You May Also Be Interested In

• Is Treasury selloff a major issue for stock market bulls?
• BofA Securities Reiterates Buy Rating on Micron Technology (MU); Sees $230+ in EPS by FY30
• Bernstein SocGen: 'Investor day makes us more bullish on SanDisk (SNDK)'